WO2024051762 - ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/051762
Publication Date
14.03.2024
International Application No.
PCT/CN2023/117376
International Filing Date
07.09.2023
Title **
[English]
ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-TROP2/EGFR ET LEURS UTILISATIONS
Applicants **
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
Inventors
LI, Zhuolin
GUAN, Xuewa
SHANG, Chengzhang
SHEN, Yuelei
Priority Data
PCT/CN2022/117496
07.09.2022
CN
PCT/CN2023/083228
23.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3168 | |
| EPO | Filing, Examination, Granting | 29027 | |
| Japan | Filing, Examination, Granting | 3108 | |
| South Korea | Filing, Examination, Granting | 3971 | |
| USA | Filing, Examination, Granting | 14790 |
Total:
54,064
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The anti-TROP2/EGFR antibodies, and antibody drug conjugates derived therefrom, specifically bind to at least two different antigens EGFR and TROP2.[French]
L'invention concerne des anticorps anti-TROP2/EGFR et des conjugués anticorps-médicament dérivés de ceux-ci, qui se lient spécifiquement à au moins deux antigènes différents EGFR et TROP2.